Koch Marcus W, Murray T Jock, Fisk John, Greenfield Jamie, Bhan Virender, Jacobs Philip, Brown Murray, Metz Luanne M
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
J Neurol Sci. 2014 Jun 15;341(1-2):51-4. doi: 10.1016/j.jns.2014.03.047. Epub 2014 Apr 2.
The nine hole peg test (9HPT) is an emerging outcome measure in clinical trials in multiple sclerosis (MS). In this study we investigated how performance on the 9HPT at baseline is related to annualized direct MS related cost.
We enrolled patients with a definite diagnosis of MS from two Canadian MS centers. 9HPT and demographic information were recorded at baseline, and patients prospectively recorded all MS related costs for 6months. Costs were compared among five groups according to the baseline 9HPT, and we built a multiple linear regression model including cost (dependent variable) and 9HPT at baseline, age, disease duration, sex and disease course (independent predictor variables).
We analyzed data from 298 patients. Cost significantly increased with increasing 9HPT scores (p<0.0001), with the costs for health care providers, changes to the home or car and long-term care dominating in the most disabled patient groups. The 9HPT score was a significant predictor of cost in the regression model (p=0.006).
Performance on the 9HPT is closely related to cost. Our data add another aspect of patient relevance to using the 9HPT as an outcome measure in clinical trials.
九孔插板试验（9HPT）是多发性硬化症（MS）临床试验中一种新出现的疗效指标。在本研究中，我们调查了基线时9HPT的表现与MS相关的年度直接成本之间的关系。
我们从两个加拿大MS中心招募了确诊为MS的患者。在基线时记录9HPT和人口统计学信息，患者前瞻性记录6个月内所有与MS相关的费用。根据基线9HPT将患者分为五组并比较费用，我们构建了一个多元线性回归模型，纳入费用（因变量）以及基线时的9HPT、年龄、病程、性别和疾病进程（自变量）。
我们分析了298例患者的数据。随着9HPT评分增加，费用显著增加（p<0.0001），在残疾程度最高的患者组中，医疗服务提供者、家庭或汽车改造以及长期护理方面的费用占主导。在回归模型中，9HPT评分是费用的显著预测因素（p=0.006）。
9HPT的表现与费用密切相关。我们的数据为在临床试验中使用9HPT作为疗效指标增加了与患者相关的另一个方面。
